Tang Capital Management’s Harmony Biosciences HRMY Stock Holding History

Tang Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-290,292	Closed	-$10.9M	–	60
2025 Q4	$10.9M	Buy	290,292 +9,092	+3%	+$299K	0.54%	36
2025 Q3	$7.75M	Hold	281,200	–	–	0.3%	76
2025 Q2	$8.89M	Hold	281,200	–	–	0.45%	58
2025 Q1	$9.33M	Hold	281,200	–	–	0.52%	48
2024 Q4	$9.68M	Hold	281,200	–	–	0.64%	44
2024 Q3	$11.2M	Hold	281,200	–	–	0.8%	42
2024 Q2	$8.48M	Hold	281,200	–	–	0.86%	38
2024 Q1	$9.44M	Buy	281,200 +10,000	+4%	+$321K	0.98%	36
2023 Q4	$8.76M	Hold	271,200	–	–	0.81%	34
2023 Q3	$8.89M	Hold	271,200	–	–	1.25%	25
2023 Q2	$9.54M	Sell	271,200 -50,000	-16%	-$1.73M	1.41%	23
2023 Q1	$10.5M	Buy	321,200 +40,000	+14%	+$1.82M	1.56%	20
2022 Q4	$15.5M	Sell	281,200 -28,800	-9%	-$1.58M	2.25%	14
2022 Q3	$13.7M	Buy	310,000 +10,000	+3%	+$488K	1.68%	20
2022 Q2	$14.6M	Hold	300,000	–	–	2.22%	13
2022 Q1	$14.6M	Buy	+300,000	New	+$12.2M	2.92%	10

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Tang Capital Management's HRMY Position: Q1 2026 in Review

Tang Capital Management sold out of Harmony Biosciences (HRMY) in Q1 2026, closing a stake of 290,292 shares — an estimated $10.9M sold.

Tang Capital Management first reported a position in HRMY in Q1 2022 and held it in 16 quarters. The position peaked at $15.5M in Q4 2022. 311 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

Tang Capital Management reported no remaining Harmony Biosciences position as of Q1 2026 after selling out during the quarter.
Tang Capital Management sold 290,292 Harmony Biosciences shares in Q1 2026, an estimated $10.9M.
Tang Capital Management first reported a position in Harmony Biosciences in Q1 2022 and held it in 16 quarters.
Tang Capital Management's Harmony Biosciences position peaked at $15.5M in Q4 2022.
311 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Tang Capital Management's 13F filing for Q1 2026, filed 15 May 2026.